SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Gattinger Pia)
 

Search: WFRF:(Gattinger Pia) > Vaccine based on fo...

  • Gattinger, Pia (author)

Vaccine based on folded RBD-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • 2022-04-15
  • Wiley,2022
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:su-204370
  • https://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-204370URI
  • https://doi.org/10.1111/all.15305DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the ongoing global COVID-19 pandemic. One possibility to control the pandemic is to induce sterilizing immunity through the induction and maintenance of neutralizing antibodies preventing SARS-CoV-2 from entering human cells to replicate in.Methods: We report the construction and in vitro and in vivo characterization of a SARS-CoV-2 subunit vaccine (PreS-RBD) based on a structurally folded recombinant fusion protein consisting of two SARS-CoV-2 Spike protein receptor-binding domains (RBD) fused to the N- and C-terminus of hepatitis B virus (HBV) surface antigen PreS to enable the two unrelated proteins serving as immunologic carriers for each other.Results: PreS-RBD, but not RBD alone, induced a robust and uniform RBD-specific IgG response in rabbits. Currently available genetic SARS-CoV-2 vaccines induce mainly transient IgG1 responses in vaccinated subjects whereas the PreS-RBD vaccine induced RBD-specific IgG antibodies consisting of an early IgG1 and sustained IgG4 antibody response in a SARS-CoV-2 naive subject. PreS-RBD-specific IgG antibodies were detected in serum and mucosal secretions, reacted with SARS-CoV-2 variants, including the omicron variant of concern and the HBV receptor-binding sites on PreS of currently known HBV genotypes. PreS-RBD-specific antibodies of the immunized subject more potently inhibited the interaction of RBD with its human receptor ACE2 and their virus-neutralizing titers (VNTs) were higher than median VNTs in a random sample of healthy subjects fully immunized with registered SARS-CoV-2 vaccines or in COVID-19 convalescent subjects.Conclusion: The PreS-RBD vaccine has the potential to serve as a combination vaccine for inducing sterilizing immunity against SARS-CoV-2 and HBV by stopping viral replication through the inhibition of cellular virus entry.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Kratzer, Bernhard (author)
  • Tulaeva, Inna (author)
  • Niespodziana, Katarzyna (author)
  • Ohradanova-Repic, Anna (author)
  • Gebetsberger, Laura (author)
  • Borochova, Kristina (author)
  • Garner-Spitzer, Erika (author)
  • Trapin, Doris (author)
  • Hofer, GerhardStockholms universitet,Institutionen för material- och miljökemi (MMK)(Swepub:su)geho3329 (author)
  • Keller, Walter (author)
  • Baumgartner, Isabella (author)
  • Tancevski, Ivan (author)
  • Khaitov, Musa (author)
  • Karaulov, Alexander (author)
  • Stockinger, Hannes (author)
  • Wiedermann, Ursula (author)
  • Pickl, Winfried F. (author)
  • Valenta, Rudolf (author)
  • Stockholms universitetInstitutionen för material- och miljökemi (MMK) (creator_code:org_t)

Related titles

  • In:Allergy. European Journal of Allergy and Clinical Immunology: Wiley77:8, s. 2431-24450105-45381398-9995

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view